# Tear Film Interferometry, Meibography, and Optical Coherence Tomography Angiography for Rosacea

**Authors:** Matteo Capobianco, Marco Zeppieri, Federico Visalli, Francesco Pellegrini, Leandro Inferrera, Rosa Giglio, Irene Gattazzo, Francesco Cappellani, Fabiana D’Esposito, Caterina Gagliano

PMC · DOI: 10.3390/diseases14030105 · 2026-03-12

## TL;DR

This study shows that eye surface changes in rosacea patients can be detected early using non-invasive imaging, even before visible symptoms appear.

## Contribution

The paper introduces a non-invasive imaging workflow combining tear film interferometry and meibography to detect subclinical ocular changes in rosacea.

## Key findings

- Tear film lipid-layer thickness was significantly reduced in rosacea patients compared to controls.
- Meibomian gland loss scores were markedly worse in rosacea patients, even without clinical ocular involvement.
- OCT-A retinal metrics showed no significant differences between groups in this small study.

## Abstract

Background/Objectives: Rosacea is a chronic inflammatory dermatosis that may involve the eye, causing surface and adnexal damage that can precede cutaneous signs. Detecting subclinical ocular changes is clinically important because early ocular surface dysfunction may be missed on routine examination yet progress to corneal complications, allowing earlier preventive management when identified. We prospectively evaluated subclinical ocular alterations in cutaneous rosacea using a combined, fully non-invasive high-tech imaging workflow—tear film interferometry, infrared meibography, and exploratory retinal optical coherence tomography angiography (OCT-A)—including patients without clinically evident ocular involvement. Methods: Sixteen patients with cutaneous rosacea (mean age 44.3 ± 11.2 years; 4 males, 12 females) were enrolled and divided into: Group 1—rosacea with clinically evident ocular involvement (n = 11); Group 2—rosacea without clinical ocular involvement (n = 5). Six age-matched healthy subjects served as controls (Group 3). All underwent LipiView II® interferometry and meibography to quantify lipid-layer thickness (LLT, nm) and meibomian gland (MG) loss score (1 = normal–4 = severe), plus retinal OCT-A (Optovue Inc., Fremont, CA, USA). ANOVA with post hoc Tukey test assessed inter-group differences. Results: OCT-A showed no significant alterations in superficial or deep retinal plexuses across groups (p > 0.05). Conversely, LLT was significantly reduced in both rosacea groups vs. controls (OD: 45.5 ± 21.4 nm and 67.4 ± 10.1 nm vs. 92.7 ± 8.2 nm; OS: 40.4 ± 15.3 nm and 66.4 ± 10.1 nm vs. 96.0 ± 6.7 nm; p < 0.001). MG score was markedly higher (worse) in rosacea (OD: 3.63 ± 0.50 and 3.20 ± 0.83 vs. 1.83 ± 0.75; OS: 3.45 ± 0.68 and 3.40 ± 0.54 vs. 1.66 ± 0.81; p < 0.001). Ocular symptoms were reported by 85% of patients yet slit-lamp examination revealed surface alterations in 58% of asymptomatic cases. Conclusions: Tear film interferometry and meibography detect early ocular surface impairment in rosacea—even in the absence of clinical signs—while retinal microvasculature appears unaffected. Routine ophthalmologic screening of all rosacea patients could enable prompt treatment of subclinical dysfunction, potentially preventing corneal complications. Retinal OCTA metrics were not significantly different in this small pilot cohort, and these negative findings should be interpreted cautiously pending larger studies.

## Linked entities

- **Diseases:** rosacea (MONDO:0006604)

## Full-text entities

- **Genes:** TAC1 (tachykinin precursor 1) [NCBI Gene 6863] {aka Hs.2563, NK2, NKNA, NPK, TAC2}, VEGFA (vascular endothelial growth factor A) [NCBI Gene 7422] {aka L-VEGF, MVCD1, VEGF, VPF}
- **Diseases:** pan-ocular microangiopathy (MESH:C537931), neurovascular (MESH:D013901), atopic dermatitis (MESH:D003876), dry eye (MESH:D015352), anterior segment disease (MESH:C537775), OCT-A abnormalities (MESH:C537669), gland loss (MESH:D000307), atrophy (MESH:D001284), cutaneous disease (MESH:D004194), photophobia (MESH:D020795), posterior-segment microangiopathy (MESH:C537538), corneal complications (MESH:D003316), Ocular Surface Disease (MESH:D010534), Ocular disease (MESH:D005128), MG (MESH:D000080343), vascular dysregulation (MESH:D021081), erythema (MESH:D004890), Rosacea (MESH:D012393), retinal vascular disease (MESH:D012164), dryness (MESH:D014987), telangiectasia (MESH:D013684), meibomian (MESH:D000092663), autoimmune or connective tissue disease (MESH:D003240), papules (MESH:D000169), pupil dilatation (MESH:D011681), lupus erythematosus (MESH:D008180), tear (MESH:D012167), injury to (MESH:D014947), keratitis (MESH:D007634), conjunctival and eyelid abnormalities (MESH:D005141), diabetes mellitus (MESH:D003920), vasculopathy (MESH:D000090122), psoriasis (MESH:D011565), inflammatory (MESH:D007249), vascular abnormalities (MESH:D014652), inflammatory dermatosis (MESH:D012871), conjunctival hyperemia (MESH:D003229), blepharitis (MESH:D001762), corneal involvement (MESH:C537363), LLT (MESH:D011017)
- **Chemicals:** isotretinoin (MESH:D015474), OCT (MESH:C051883), tropicamide (MESH:D014331), doxycycline (MESH:D004318), LipiView (-), brimonidine (MESH:D000068438), cyclosporine (MESH:D016572), Lipid (MESH:D008055), alcohol (MESH:D000438), A (MESH:D001151)
- **Species:** Demodex folliculorum (species) [taxon 481310], Homo sapiens (human, species) [taxon 9606]

## Figures

2 figures with captions in the complete paper: https://tomesphere.com/paper/PMC13025564/full.md

---
Source: https://tomesphere.com/paper/PMC13025564